Release Date: 14/09/12 10:18 Summary: WAM Capital and Premium to merge Price Sensitive: No Download Document 33.51KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%